Astellas set to purchase Audentes Therapeutics Inc. for $3 billion

On Tuesday Astellas Pharma Inc., the Japan-based pharmaceutical firm stated how it had decided on a contract to purchase Audentes Therapeutics Inc., the United States-based biotechnology company, for nearly $3 billion to advance the generation of genetic medicines. 

Audentes Therapeutics studies and generates treatments for severe neuromuscular ailments. The company’s attainment by Astellas is predicted to be concluded in ....